Cite

HARVARD Citation

    Weekes, C. et al. (2020). A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC‐0994 in Patients with Advanced Solid Tumors. Oncologist. pp. 833-e1438. [Online]. 
  
Back to record